Incyte Corp. (INCY)

86.02
NASDAQ : Health Technology
Prev Close 85.34
Day Low/High 84.21 / 86.06
52 Wk Low/High 57.00 / 88.83
Avg Volume 1.49M
Exchange NASDAQ
Shares Outstanding 214.05M
Market Cap 18.29B
EPS 0.50
P/E Ratio 167.33
Div & Yield N.A. (N.A)

Latest News

Data From Incyte's Cancer Research Portfolio To Be Featured In Seven Abstracts At The AACR Annual Meeting 2019

Data From Incyte's Cancer Research Portfolio To Be Featured In Seven Abstracts At The AACR Annual Meeting 2019

Incyte Corporation (Nasdaq:INCY) announces that seven abstracts showcasing data from its cancer research portfolio will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2019.

Incyte To Present At Upcoming Investor Conferences

Incyte To Present At Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: Cowen and Company 39 th Annual Health Care Conference on Monday, March 11, 2019 at 12:00 pm (EDT) in Boston; and...

Incyte Reports 2018 Fourth Quarter And Year-End Financial Results, Provides 2019 Financial Guidance And Provides Updates On Key Clinical Programs

Incyte Reports 2018 Fourth Quarter And Year-End Financial Results, Provides 2019 Financial Guidance And Provides Updates On Key Clinical Programs

Incyte Corporation (Nasdaq:INCY) today reports 2018 fourth quarter and year-end financial results, announces 2019 guidance and provides a status update on the Company's development portfolio.

Incyte Expected to Earn 17 Cents a Share

Incyte Expected to Earn 17 Cents a Share

Incyte revenue expected to rise 9.5% to $486.2 million.

Incyte Becomes #35 Most Shorted Nasdaq 100 Component, Replacing Texas Instruments

Incyte Becomes #35 Most Shorted Nasdaq 100 Component, Replacing Texas Instruments

The most recent short interest data has been released for the 01/31/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALGT, ANGI, BHE, GRA, HPJ, INCY, KN, LND, MLAB, NR, TDC, TZOO, VLY Downgrades: ASYS, DX, FFG, HAS Initiations: FSCT Read on to get TheStreet Quant Ratings' detailed report:

Lilly Announces Top-Line Phase 3 Results For Baricitinib In Patients With Moderate To Severe Atopic Dermatitis

Lilly Announces Top-Line Phase 3 Results For Baricitinib In Patients With Moderate To Severe Atopic Dermatitis

INDIANAPOLIS, Feb. 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase 3 studies evaluating the efficacy and...

Incyte To Report Fourth Quarter And Year-end Financial Results

Incyte To Report Fourth Quarter And Year-end Financial Results

Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2018 financial results conference call and webcast for 8:00 a.

Incyte Announces First Patient Treated In Phase 3 Clinical Trial Of Itacitinib For Chronic Graft-Versus-Host Disease

Incyte Announces First Patient Treated In Phase 3 Clinical Trial Of Itacitinib For Chronic Graft-Versus-Host Disease

Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in GRAVITAS-309, a pivotal Phase 3 trial for the first-line treatment of patients with chronic graft-versus-host disease (GVHD).

The New #24 Most Shorted Nasdaq 100 Component: Incyte

The New #24 Most Shorted Nasdaq 100 Component: Incyte

The most recent short interest data has been released for the 12/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Incyte Climbs on Guggenheim Upgrade

Incyte Climbs on Guggenheim Upgrade

Shares of Incyte Corporation climbed Thursday after Guggenheim Partners upgraded the biopharmaceutical company from nuetral to buy.

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

Incyte Appoints Christiana Stamoulis As Chief Financial Officer

Incyte Appoints Christiana Stamoulis As Chief Financial Officer

Incyte (Nasdaq:INCY) today announced the appointment of Christiana Stamoulis as Executive Vice President and Chief Financial Officer, effective February 11, 2019.

Incyte Announces First Patient Treated In Phase 3 Clinical Trial Program For Ruxolitinib Cream In Atopic Dermatitis

Incyte Announces First Patient Treated In Phase 3 Clinical Trial Program For Ruxolitinib Cream In Atopic Dermatitis

Incyte (Nasdaq:INCY) today announced that the first patient has been treated in the Phase 3 TRuE-AD clinical trial program evaluating the long-term safety and efficacy of ruxolitinib cream as monotherapy for adolescent and adult patients (age ≥ 12 years)...

Http://innoventbio.com/en/

Http://innoventbio.com/en/

Incyte (NASDAQ:INCY) and Innovent Biologics, Inc. (Innovent) (HKEX: 01801) today announced that the companies, through their respective subsidiaries, have entered into a strategic collaboration agreement for three clinical-stage product candidates...

Innovent And Incyte Announce Strategic Collaboration And Licensing Agreement For Three Clinical-stage Product Candidates In China

Innovent And Incyte Announce Strategic Collaboration And Licensing Agreement For Three Clinical-stage Product Candidates In China

SUZHOU, China, Dec. 16, 2018 /PRNewswire/ -- Innovent Biologics, Inc.

Incyte To Present At Upcoming Investor Conferences

Incyte To Present At Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of January: Goldman Sachs 11 th Annual Healthcare CEOs Unscripted: A View from the Top Conference on Thursday, January 3, 2019 at...

FDA Grants Fast Track Designation To The Baricitinib Development Program For The Treatment Of Systemic Lupus Erythematosus (SLE)

FDA Grants Fast Track Designation To The Baricitinib Development Program For The Treatment Of Systemic Lupus Erythematosus (SLE)

INDIANAPOLIS, Dec. 13, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.

Results Of REACH1 Study Of Ruxolitinib (Jakafi®) For The Treatment Of Acute Graft-Versus-Host Disease Demonstrate Rapid And Durable Patient Benefit

Results Of REACH1 Study Of Ruxolitinib (Jakafi®) For The Treatment Of Acute Graft-Versus-Host Disease Demonstrate Rapid And Durable Patient Benefit

Incyte Corporation (Nasdaq:INCY) announces updated results from its pivotal Phase 2 REACH1 study evaluating ruxolitinib (Jakafi ®) in combination with corticosteroids as a treatment for patients with acute graft-versus-host disease (GVHD) who have had an...

Incyte Becomes #29 Most Shorted Nasdaq 100 Component, Replacing Twenty-First Century Fox

Incyte Becomes #29 Most Shorted Nasdaq 100 Component, Replacing Twenty-First Century Fox

The most recent short interest data has been released for the 11/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Incyte Appoints Dr. Dashyant Dhanak As Chief Scientific Officer

Incyte Appoints Dr. Dashyant Dhanak As Chief Scientific Officer

Incyte (NASDAQ:INCY) today announced the appointment of Dashyant Dhanak, Ph.D.

Incyte To Present At Upcoming Investor Conference

Incyte To Present At Upcoming Investor Conference

Incyte Corporation (Nasdaq:INCY) announced today that it will present at Evercore ISI HEALTHCONx on Wednesday, November 28, 2018 at 3:30 pm EST in Boston.

Multiple Abstracts Highlighting Data From Incyte's Targeted Therapy Portfolio Accepted For Presentation At The 60th Annual ASH Meeting

Multiple Abstracts Highlighting Data From Incyte's Targeted Therapy Portfolio Accepted For Presentation At The 60th Annual ASH Meeting

Incyte (Nasdaq:INCY) announces that multiple abstracts, including data from its clinical development programs for ruxolitinib (Jakafi ®), pemigatinib and INCB50465 will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting 2018...

Incyte Reports 2018 Third Quarter And Nine Month Financial Results And Provides Updates On Key Clinical Programs

Incyte Reports 2018 Third Quarter And Nine Month Financial Results And Provides Updates On Key Clinical Programs

Incyte Corporation (Nasdaq:INCY) today reports 2018 third quarter and nine month financial results and provides a status update on the Company's development portfolio.

Incyte Named A 2018 Top Employer By Science Magazine

Incyte Named A 2018 Top Employer By Science Magazine

Incyte Corporation (Nasdaq:INCY) announced today that it has been named one of the global biotechnology and pharmaceutical industry's top employers by Science magazine, ranking second on the list of only 20 companies recognized in the publication's annual...

FDA Grants Priority Review For Ruxolitinib (Jakafi®) As A Treatment For Patients With Acute Graft-Versus-Host Disease

FDA Grants Priority Review For Ruxolitinib (Jakafi®) As A Treatment For Patients With Acute Graft-Versus-Host Disease

Incyte Corporation (Nasdaq:INCY) today announced that the U.S.

ACR 2018: Lilly Shares Updated Safety Analysis Of OLUMIANT® (baricitinib) In Patients With Moderately-to-Severely Active Rheumatoid Arthritis

ACR 2018: Lilly Shares Updated Safety Analysis Of OLUMIANT® (baricitinib) In Patients With Moderately-to-Severely Active Rheumatoid Arthritis

- Integrated safety analysis reflects long-term results from 3,492 treated patients for 7,860 patient-years of exposure -

TheStreet Quant Rating: C+ (Hold)